PDX Research Hub
Pharmacodiagnostics — bringing the lab to the pharmacy. One question, studied across five areas: can pharmacists generate, interpret, and act on diagnostic data right where the medication decision happens?
Test Explorer
test · category · machine · what it tells youPick a test to see what it measures, what a result reveals, and whether it can screen.
Learn
No science background needed — pick any question; each answer stands on its own.
What is a lab test — and what is a panel?
A test measures one substance — an analyte (the specific thing being measured: glucose, sodium, a particular protein). One analyte, one result. A panel isn't a different kind of measurement — it's a billing bundle of individual tests run together from one blood draw. You stick the patient once; the analyzer reads many analytes off that single sample.
What machines run these tests — and what does “point-of-care” mean?
Point-of-care (POC) is not a machine — it’s a setting. It means the test is run right where the patient is, with a result in minutes, instead of shipping the sample to a central lab. POC devices are small, often handheld, and usually CLIA-waived — which is exactly why they are the realistic starting point for a pharmacy.
The machine families are a separate question — the kind of instrument that does the chemistry: chemistry, hematology, immunoassay, coagulation, and molecular analyzers. The same test can live in either world: A1c can run on a benchtop chemistry analyzer in a central lab, or on a small waived POC device in a pharmacy — same test, different setting.
Specific devices, costs, and throughput fill in as the Machines section is built.
How do you pay for a lab machine?
Mostly, you don’t buy it outright. The common model is reagent rental / placement: the vendor places the instrument at little or no upfront cost, and you commit to buying its per-test reagents — the cartridges, discs, or strips. Service, warranty, installation, and operator training are usually bundled into that agreement. A few examples make it concrete: the Afinion 2 is often placed for $0 against a reagent commitment, and the Sofia 2 is typically leased.
The alternatives are a fixed-monthly lease, or an outright purchase (handhelds run a few hundred dollars; benchtops, low-to-mid thousands; high-end molecular boxes far more). Because vendors quote against your projected test volume, public sticker prices barely exist — the real figures surface on the refurbished and secondary market, which is where the per-device costs in the Machines section come from.
What is CLIA, and why does it decide so much?
CLIA (the federal lab law) sorts every test into a complexity category: Waived, Moderate, or High. The real jump isn't evenly spaced — it's the wall between Waived and everything above. Below the wall you just follow instructions; above it you are legally a laboratory, with a director, quality control, proficiency testing, and inspections.
One more thing that trips people up: complexity is assigned to a test on a specific device, not to the machine. The FDA rates each device’s version of a test, so the “same” test can be waived on a simple handheld and moderate on a big analyzer. A device gets called “waived” as shorthand when every test on its menu is waived — and that’s no accident: makers design point-of-care boxes to clear the waived bar, because that’s what lets a pharmacy run them on just a Certificate of Waiver. Waived still means a permit and trained operators — the lightest tier, not no rules. (And not every device clears it: the Afinion is waived for its HbA1c but moderate for its ACR cartridge — one box, two ratings.)
Who is allowed to run a test — and what's a permit?
Permits aren't per-test — they're per-site, and the tier is set by the single highest-complexity test on your menu. They stack across three levels of government, and you climb all three at once. A “permit” is the certificate that says your site is allowed to run that tier of testing.
How does a test actually get paid for?
Every insurance claim needs two codes that must agree. CPT (from the AMA) says what you did — e.g., 80053 for a metabolic panel. ICD-10 says why — the diagnosis that justifies it. If the “why” doesn't support the “what,” the claim is denied. That match is called medical necessity, and it's the hinge the whole financial model turns on.
The same procedure can be free or cost-shared depending only on the “why.” An HbA1c (CPT 83036) billed with diabetes screening (ICD-10 Z13.1) is a covered, no-cost-share preventive test. The same 83036, billed to work up a patient’s symptoms, is diagnostic — and the patient pays a share.
What makes a test “preventive”?
Some screenings must be covered with no copay. Under the ACA, services the USPSTF grades A or B are required to be covered in full by most plans. The trick: the same test is “preventive” (no cost-share, billed with a screening code) or “diagnostic” (cost-shared) depending on why it's run. Pharmacists can already order many preventive tests — PDX is about doing it where the patient already is. That's why every test record carries a clinical screening-capable flag, including a yellow “maybe” for the frontier we want to expand.
The three payer lanes reach that no-cost-share point by different routes. Commercial plans follow the ACA mandate directly. Medicare carries its own list of covered preventive services, which overlaps heavily with the USPSTF grades. Medi-Cal (California's Medicaid) covers the A/B set as well. What none of this settles is the per-plan detail — frequency limits, prior authorization, and whether a pharmacist can bill as the performing provider.
For PDX the takeaway is blunt: the clinical case and the coverage case are the same case. The preventive screenings a pharmacist can perform are largely already covered — the open question is whether a pharmacist can bill for performing them.
Devices
Every device in the catalog. Search, or filter by complexity tier, discipline, or maker — tap any device for its fact sheet.
Manufacturers
The companies behind the devices. Tap any maker for a short profile and links to its analyzers.
Codes
Two codes per claim — what was done (CPT) and why (ICD-10). They have to agree to get paid, and the “why” is what makes a screening free.
Checklists
Every credential it takes to run lab tests — large or small. Two players carry different loads: a teaching or pilot lab doing non-waived testing carries the full set; a pharmacy running a waived point-of-care menu carries a lighter one. Tap any credential to open its page, or use the apply link to jump to its application.
Certificates
The five federal CLIA certificate types, lowest to highest. The one you hold is set by the highest-complexity test on your menu. Tap any to open its page.
Exemptions
There’s no blanket rule that lets a university skip lab law. But one federal carve-out defines a sandbox the school can work in right now — and a single question decides which side of the line you’re on. This is a first-pass map, not legal advice.
Federal law has a research exception (CLIA, 42 CFR §493.3(b)(2)): a lab that tests human specimens but does not report patient-specific results to diagnose, treat, or assess an individual’s health is exempt from CLIA certification. So the line isn’t whether you’re a school, or whether you charge — it’s whether one person’s result leaves the lab to guide that person’s care. Aggregate findings (“12 of 30 samples were positive”) stay inside the exception; a result returned to a named patient for their care does not.
- Train students on instruments, blood draws, and lab workflow.
- Develop and validate testing methods.
- Run quality-control, proficiency, or de-identified samples.
- Generate aggregate research data not tied to any individual’s care.
California follows the same logic for research not used in patient care, though the state license-or-registration question should be confirmed with CDPH Laboratory Field Services before relying on it — verify.
Hand one patient one result they (or their pharmacist or doctor) could act on, and the exception disappears. Now it’s clinical testing, and everything applies: a federal CLIA certificate, a California license or registration, a qualified director, licensed personnel for non-waived tests, and proficiency testing. There is no university exemption from this — the full list is on Checklists. Three real ways to operate out here:
- Waived-only path — not an exemption, but the lightest real-patient lane: a Certificate of Waiver plus California registration lets the pharmacy run waived point-of-care tests (A1c, lipids, rapid strep/flu) on real patients with minimal overhead.
- Trainee licenses — California CLS and MLT trainee licenses let students perform non-waived tests inside an approved program under supervision. A pathway, not a bypass.
- Partner with a licensed lab — an already-credentialed lab does or oversees the testing while the pharmacist acts on the result. This is how most pilots sidestep the credential wall.
The school can stand up a teaching and research lab now, under the research exception — to train students, validate the model, and gather data — as long as it doesn’t return patient results for care. To run the real PDX loop (a pharmacist acting on a patient’s result in the same visit), you’re outside the sandbox: get the credentials, or partner with a licensed lab. And the long-term ask at the heart of PDX — a pharmacist independently directing a moderate- or high-complexity lab — is not an existing exemption. California limits that role to physicians and doctoral scientists, so it would take a regulatory or statutory change, not a carve-out. That’s the “what would it take to do more” question the rest of the project works toward.
Current Scope
Putting a lab in a pharmacy sounds like a regulatory wall. It mostly isn’t — almost every version worth piloting is legal today, and the one piece that isn’t is a hire, not a new law.
The only hard item on that list — a qualified director — is a person to hire, not a form to file.
Education
What a pharmacist must learn for the model, against what the PharmD already covers.
This layer compares what the model would require a pharmacist to learn — phlebotomy, sample handling, CLIA compliance, instrument operation, quality control, and result interpretation — against what the PharmD curriculum and licensure already cover, to define the minimum added training. It depends on the operational model (Devices) and the legal boundary (Regulatory) being settled first.
Coverage
Who pays, and under what rules.
This layer maps who pays for pharmacist-performed testing and under what rules — Medicare Part B limits, pharmacist provider status, and the billing pathways that decide whether the model is financially viable. It pairs with the Codes section and feeds the Proposal.
Case Studies
The evidence that pharmacist-led testing and care improve outcomes. Each entry: the study, its key findings, and a link to the source.
A 13-month pilot at two Kaiser Permanente outpatient pharmacies let pharmacists order HbA1c labs and run extended adherence consultations for diabetes patients who were nonadherent to their oral medications (HbA1c ≥ 8% or missing their annual test), measured against usual provider-ordered care.
- Of 793 HbA1c orders, 87 were pharmacist-initiated and 706 came through usual care.
- Far more pharmacist-group patients reached an HbA1c below 8% — 34.9% vs 12.2% — a statistically significant gap.
- The pharmacist group's average HbA1c fell from 9.47% to 8.68% (a significant 0.79-point drop); the usual-care group barely moved (9.70% to 9.43%, not significant).
- Lab completion was higher in the pharmacist group (49.4% vs 39.5%), though that difference was not significant.
- The service added about 5 minutes per encounter and an hour of training, but did not increase patient wait times or reduce pharmacy productivity.
This is direct evidence under California SB 493 — the same legal basis PDX builds on — that pharmacist-linked testing can improve outcomes without disrupting pharmacy operations. It also names PDX's two hardest barriers honestly: there is no clear reimbursement model for pharmacist lab ordering, and the pharmacy needs access to the medical record (Kaiser had an integrated EMR; most community pharmacies do not).
View the study →A retrospective cohort study at a community-based health system in Virginia (2018–2019) compared adults aged 18–75 with uncontrolled type 2 diabetes who were managed by embedded pharmacists under a collaborative practice agreement (the PPCC model) against standard care in clinics without a pharmacist. The standard-care group was built by 1:2 propensity-score matching (N = 1,293; 431 in the pharmacist group).
- Patients in the pharmacist group were 3 to 5 times more likely to reach HbA1c control than standard-care patients.
- The advantage held across every glycemic threshold the study tracked (HbA1c ≤ 9%, ≤ 8%, and ≤ 7%).
- Blood-pressure control (< 140/90 mm Hg) was assessed as a co-primary quality measure alongside HbA1c.
- The outcomes measured are HEDIS quality measures — the same benchmarks managed-care plans use to set reimbursement.
- The authors conclude that managed-care organizations should integrate pharmacists into primary-care diabetes teams.
This is large-sample evidence for the action half of the PDX loop: when pharmacists act on diagnostic data (HbA1c, blood pressure) under a collaborative practice agreement, the quality measures that drive payer reimbursement measurably improve. It reinforces the glycemic / chronic-disease cluster as PDX’s strongest starting point, and the collaborative-practice-agreement structure here is exactly the kind of legal arrangement the regulatory layer would build on.
View the study →Proposal
Where everything converges — the integrated business plan and pilot.
The Proposal is assembled once the five feasibility layers are complete. It stitches the clinical, legal, operational, educational, and financial findings into one integrated case, plus a pilot design and next-step roadmap. The Clinical and Regulatory layers are furthest along; the rest follow in sequence.
About PDX
PDX puts diagnostic testing where the prescription happens — a pharmacist orders the test, reads it, and acts on it in one visit. It is an approved Chapman University School of Pharmacy elective, researched here across five areas: clinical, regulatory, operations, education, and finance.
PDX is studied as a chain: each area hands the next a narrower model. They are lenses, not boxes — a single thing (a permit, say) is legal, financial, and educational at once. Each names the hub sections it feeds.
- Pick the strongest starting service line and patient group.
- Define the pharmacist action on a result, and the referral triggers.
- Choose the first outcomes a pilot would measure.
- Separate what pharmacists can do today from what needs a protocol or a law change.
- Map the CLIA complexity wall for each test.
- Identify the permits, personnel licensure, and accreditation the site would need.
- Define the minimum viable setup: test menu, devices, workflow, QC.
- Tie each test to its machine and CLIA complexity.
- Find the operational limits on speed, scale, and staffing.
- Compare the model's required skills against today's PharmD.
- Name the training gaps (phlebotomy, QC, interpretation).
- Propose the minimum added training and how it fits at Chapman.
- Find the revenue pathways: codes, coverage, who pays.
- Map the costs: machines, staffing, permits.
- Build the break-even case that lands in the Proposal.